By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”
Medical InnovationsSpecialtiesTechnology

Cancer Immunotherapy: Combination Therapy May Be the “Way of the Future”

Deanna Pogorelc
Deanna Pogorelc
Share
4 Min Read
chemotherapy
SHARE

chemotherapyFirst published on MedCityNews.com. Efforts to overcome the unusual ability of cancer cells to dodge the body’s immune response have reached an inflection point this year.

chemotherapyFirst published on MedCityNews.com. Efforts to overcome the unusual ability of cancer cells to dodge the body’s immune response have reached an inflection point this year. And, at least according to some experts, commercial interest in cancer immunotherapies has gone through the roof.

“If you had asked most Big Pharmas in the beginning of 2013 if they were interested in immunotherapy, they would have said ‘not necessary, we’re (more) in small molecules,’” explained Marc Mansour, chief operating officer of Canadian vaccine developer Immunovaccine, in an interview last month.

But by the end of the American Society of Clinical Oncology’s annual conference this summer, the sentiment had shifted. Both Bristol-Myers Squibb and Merck presented solid early-stage data on their respective PD-1 inhibitors that added to excitement that’s been building over the past several years around immunotherapy.

More Read

online portal
NCOA Announces New Online Portal for Older Adults Seeking Employment
Life-Saving Technology: Understanding the Importance of Reliable Medical Monitors
No More Monkeys Jumping On This Bed: Few Psych Meds Coming Our Way
Patientnado: The Healthcare Storm Is About to Hit
How Some People in California Enjoy Exceptional Dental Care

Since then, AstraZeneca, for one, has added to its cancer portfolio of small molecule drugs and biologics with a $500 million buyout of Amplimmune in August. Bayer also signed an agreement with Compugen to research, develop and commercialize immunotherapies. Then there’s Roche, which signed deals with Inovio Pharmaceuticals and Germany’s immatics.

Both Bristol-Myers Squibb and Merck’s candidates are PD-1 inhibitors, which fall under an especially promising class of drugs being called immune checkpoint inhibitors.

“At least five or six pharmaceutical companies are conducting clinical trials on checkpoint inhibitors, and I think that we’re going to see approvals probably in the next year or two,” said Dr. James Gulley, director of medical oncology services at the National Cancer Institute’s Center for Cancer Research.

Bristol-Myers Squibb’s Yervoy, FDA approved in 2011 for treatment of melanoma, was the first checkpoint inhibitor on the market. A second generation of drugs in this area seem to be better tolerated but induce just as much immune activity, he said.

The real potential, though, lies in the ability of these inhibitors to be combined with other kinds of drugs, like vaccines. Gulley explained that vaccines – like the ones being developed my Immunovaccine, Merck, GSK and others – would act as the “gas” and the “steering” that would turn on the immune system and set its aim to fight cancerous cells. Then the checkpoint inhibitors would disable the “brake” – the body’s tendency to turn off the immune response once it’s killed the infected cells.

“Combination therapy is the way of the future,” Immunovaccine’s Mansour reiterated. For an upcoming phase 2 clinical trial in brain cancer, the company is pairing its vaccine candidate with temozolomide, an immune modulator that’s the standard therapy for newly diagnosed gliobastoma patients after surgery and radiation.

“But, it can’t be a $100K therapy on top of another $100K therapy,” he added. That’s one of the big industry takeaways from Dendreon’s Provenge, the first immunotherapy to be approved by the FDA back in 2010. The therapy, which requires a patient’s immune cells to be sent to a lab where they’re reprogrammed to attack cancer cells, and then sent back and injected back into the patient, has been met with weak sales that have forced the drugmaker to restructure.

“That’s not sustainable,” Mansour summed up. “We have to push to find therapies that work, and you have to think about it as a therapy rather than a compound.”

[Image credit: Flickr user Phil and Pam]

TAGGED:cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Specialties

Medical Marijuana For Cancer Patients: Potential Relief And Benefits

November 29, 2018
african american dermal filler
SkinSpecialties

Where to Inject Dermal Fillers for African American Patients?

January 22, 2024
wearable tech
Medical InnovationsTechnology

How Familiar Technology Is Being Used to Advance Digital Health

September 21, 2014

Chat 129: An Apps Pharmacy Coming to a Neighbourhood Near You?

May 30, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?